Biogen Inc

-9.92 (-3.66%)

Biogen Reports Positive Topline Results From Phase 2 Convey Study In Small Fiber Neuropathy

Published: 09/16/2021 11:43 GMT
Biogen Inc (BIIB) - Biogen Announces Positive Topline Results From Phase 2 Convey Study in Small Fiber Neuropathy.
Biogen - Convey Study 200 Mg Twice Daily Arm Met Primary Endpoint of Change From Baseline to Week 12 of Double-blind Period in Mean Adp Score.
Biogen - While 350 Mg Twice Daily Arm Did Not Meet Primary Endpoint, It Met Statistical Significance in Pgic at Week 12.
Biogen Inc - Both Doses of Vixotrigine Were Generally Well Tolerated.
Biogen Inc - Safety Profile of Both Doses of Vixotrigine Was Consistent With Previous Studies of Vixotrigine With No Evidence of Abuse Potential.
Biogen Inc - 5.3% of Subjects Discontinued Open-label Part of Study Due to Adverse Events.
Biogen Inc - Across Entire Study Majority of Aes Were Mild Or Moderate in Severity.
Biogen Inc - Will Further Evaluate Convey Data, Plans to Complete Phase 1 Clinical Study to Inform Potential Next Steps in Development of Vixotrigine.